Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
about
Recent advances in the diagnosis and treatment of acute myocardial infarctionHospital variability in use of anticoagulant strategies during acute myocardial infarction treated with an early invasive strategy.Risk guided use of the direct thrombin inhibitor bivalirudin: insights from recent trials and analyses.One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial.Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments.Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of ESafety and Effectiveness of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-AnalysisA Safety Evaluation of Cangrelor in Patients Undergoing PCI.Bivalirudin versus heparin and provisional GP IIb/IIIa inhibitors in patients treated for ST-segment elevation myocardial infarctions: Comparison of outcomes in a "real-world" setting.Antithrombotic Selection in ST-Segment Elevation Myocardial Infarction: a Year in Review.Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population.The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article.Antithrombotic therapy for patients with STEMI undergoing primary PCI.Bivalirudin, glycoprotein inhibitor, and heparin use and association with outcomes of primary percutaneous coronary intervention in the United Kingdom.Bivalirudin Versus Heparin: A Fight Far From Finished?: Efficacy, Safety, and Cost Remain Battlegrounds for the Treatment Of ST-Segment Elevation Myocardial Infarction.Bivalirudin or heparin for radial access?Optimal pharmacological therapy in ST-elevation myocardial infarction-a review : A review of antithrombotic therapies in STEMI.Enhancing the Benefit of Bivalirudin in Percutaneous Coronary Intervention: Is High Risk of Bleeding the Key?
P2860
Q35626702-6C2FD6FA-8D51-4E3D-B705-756C2DD3B7F9Q36142016-5F662530-1E6C-4A6B-A85F-87DB94BC3E54Q37329447-8785929E-F93C-47DC-9CD1-7494B04FD954Q38379744-EDE3EA80-7E41-4B4B-B326-AC267577D05BQ38380117-6867C8C9-E322-4C58-8CE8-8B94A35A5D44Q38423493-08E2DF77-6226-4DB4-885A-A9E01116C624Q38626782-C5618098-9863-48CA-853B-DBED3A0D75DEQ38656364-967D2B1F-815F-4D37-8158-574929989F7CQ38661324-EC4AA1C4-23CF-4115-A3D3-9D30FE273AA4Q38672923-799BD424-1490-43A1-BE9B-8D1D8918E0CCQ38736998-14DFFD8B-4632-42D4-8974-8EDACAD58A6AQ38875031-C86E317E-B783-49FB-845A-DF941CFE12E3Q39022866-72FE0B04-C57D-43C0-96CD-6B8E50C330F3Q39096073-0964F71F-AAA2-470A-857A-58EBDC854CC7Q39147735-EB67C6D1-5656-49DF-89DF-66BDC40790E4Q40191441-6997DAAF-0852-4549-A922-EF20967D59C4Q41782952-A035C213-51DA-44B1-A54D-31061B5BB23CQ48039225-2880B0DB-D7A0-45B1-B502-3763C7F375C5Q52567898-0E81525C-F6C1-4FDE-B1D2-69D5C5BEA5EAQ57551448-EB2FE335-F349-4864-AB4B-8B090460DFFE
P2860
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Bivalirudin versus heparin wit ...... RIZONS-AMI and EUROMAX trials.
@ast
Bivalirudin versus heparin wit ...... RIZONS-AMI and EUROMAX trials.
@en
type
label
Bivalirudin versus heparin wit ...... RIZONS-AMI and EUROMAX trials.
@ast
Bivalirudin versus heparin wit ...... RIZONS-AMI and EUROMAX trials.
@en
prefLabel
Bivalirudin versus heparin wit ...... RIZONS-AMI and EUROMAX trials.
@ast
Bivalirudin versus heparin wit ...... RIZONS-AMI and EUROMAX trials.
@en
P2093
P50
P1476
Bivalirudin versus heparin wit ...... RIZONS-AMI and EUROMAX trials.
@en
P2093
Arnoud Van't Hof
Bernard J Gersh
Christian W Hamm
Debra Bernstein
Efthymios N Deliargyris
Giulio Guagliumi
Gregg W Stone
Patrick Goldstein
Peter Clemmensen
Philippe Généreux
P356
10.1016/J.JACC.2014.10.029
P407
P577
2015-01-01T00:00:00Z